A novel anti-cancer effect of resveratrol: Reversal of epithelial- mesenchymal transition in prostate cancer cells

Molecular Medicine Reports

Volumn 10, Issue 4, 2014, Pages 1717-1724

  Li, Jianping ^a   Chong, Tie ^a   Wang, Ziming ^a   Chen, Haiwen ^a   Li, Hecheng ^a   Cao, Jun ^a   Zhang, Peng ^a   Li, Hongliang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Invasion; Resveratrol, prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CADHERIN; GLI1 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; MESSENGER RNA; RESVERATROL; SONIC HEDGEHOG PROTEIN; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR; VIMENTIN;

CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG PROTEINS; HUMANS; LIPOPOLYSACCHARIDES; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STILBENES; TRANSCRIPTION FACTORS; VIMENTIN;

EID: 84924219742     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2417     Document Type: Article

References (31)

1. Snyder A, Tepper JE and Slovin SF: Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future? Semin Oncol 40: 347-360, 2013.
2. Sandhu GS, Nepple KG, Tanagho YS and Andriole GL: Prostate cancer chemoprevention. Semin Oncol 40: 276-285, 2013.
3. Bhavsar T, McCue P and Birbe R: Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol 40: 259-275, 2013.
4. Franco-Chuaire ML, Magda Carolina CS and Chuaire-Noack L: Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy. Invest Clin 54: 186-205, 2013.
5. De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110, 2013.
6. Wu Q, Hou X, Xia J, et al: Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev 39: 640-646, 2013.
7. Evdokimova V, Tognon CE and Sorensen PH: On translational regulation and EMT. Semin Cancer Biol 22: 437-445, 2012.
8. Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22: 194-207, 2012.
9. Hance MW, Dole K, Gopal U, et al: Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem 287: 37732-37744, 2012.
10. Lu T, Lin WJ, Izumi K, et al: Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol 26: 1707-1715, 2012.
11. Clyne M: Prostate cancer: androgen deprivation causes EMT in the prostate. Nat Rev Urol 9: 4, 2012.
12. Fryer RA, Galustian C, Dalgleish AG and Dalgelish AG: Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol 4: 102-112, 2009.
13. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
14. Hasan MM, Yun HK, Kwak EJ and Baek KH: Preparation of resveratrol-enriched grape juice from ultrasonication treated grape fruits. Ultrason Sonochem 21: 729-734, 2014.
15. Pollack RM and Crandall JP: Resveratrol: therapeutic potential for improving cardiometabolic health. Am J Hypertens; Sep 11, 2013 (Epub ahead of print).
16. Ren Z, Wang L and Cui J: Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie 68: 689-94, 2013.
17. Whitlock NC and Baek SJ: The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer 64: 493-502, 2012.
18. Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB and Bellanger RA: Resveratrol: potential as anticancer agent. J Diet Suppl 9: 45-56, 2012.
19. Vang O, Ahmad N, Baile CA, et al: What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6: e19881, 2011.
20. Chen MC, Chang WW, Kuan YD, Lin ST, Hsu HC and Lee CH: Resveratrol inhibits LPS-induced epithelial-mesenchymal transition in mouse melanoma model. Innate Immun 18: 685-693, 2012.
21. Colas E, Pedrola N, Devis L, et al: The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 14: 715-720, 2012.
22. Liu DZ, Wang YS and Ji AG. The role of TGF-beta in the EMT of tumor cells. Sheng Li Ke Xue Jin Zhan 42: 463-466, 2011 (In Chinese).
23. Ruat M, Angot E and Traiffort E: Shh signal and its functional roles in normal and diseased brain. Med Sci (Paris) 27: 979-985, 2011 (In French).
24. Shankar S, Nall D, Tang SN, et al: Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 6: e16530, 2011.
25. Vergara D, Valente CM, Tinelli A, et al: Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett 310: 1-8, 2011.
26. Li W, Ma J and Ma Q: Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. Curr Med Chem 20: 4185-4194, 2013.
27. Wang H, Zhang H, Tang L, et al: Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis. Toxicology 303: 139-146, 2013.
28. Chen MC, Chang WW, Kuan YD, Lin ST, Hsu HC and Lee CH: Resveratrol inhibits LPS-induced epithelial-mesenchymal transition in mouse melanoma model. Innate Immun 18: 685-693, 2012.
29. Vaillant C and Monard D: SHH pathway and cerebellar development. Cerebellum 8: 291-301, 2009.
30. Panman L and Zeller R: Patterning the limb before and after SHH signalling. J Anat 202: 3-12, 2003. (Pubitemid 36503962)
31. Xu QR, Zheng X, Zan XF, Yao YM, Yang W and Liu QG: Gli1 expression and its relationship with the expression of Shh, Vimentin and E-cadherin in human hepatocellular carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28: 536-539, 2012 (In Chinese).